Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: Subanalysis from the phase 3 trial

Shock

Volumn 35, Issue 4, 2011, Pages 349-354

  Aikawa, Naoki ^a   Shimazaki, Shuji ^b   Yamamoto, Yasuhiro ^c   Saito, Hidehiko ^d   Maruyama, Ikuro ^e   Ohno, Ryuzo ^f   Hirayama, Akio ^g   Aoki, Yoshikazu ^h   Aoki, Nobuo ⁱ  

^a KEIO UNIVERSITY   (Japan)

^b KYORIN UNIVERSITY   (Japan)

^c Tokyo Rinkai Hospital   (Japan)

^d Nagoya Central Hospital   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g Tonan Hospital   (Japan)

^h Asahi Kasei Microsystems   (Japan)

ⁱ TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Coagulopathy; DIC; Heparin; Infection; Sepsis; Thrombomodulin

Indexed keywords

HEPARIN; RECOMBINANT THROMBOMODULIN; ANTICOAGULANT AGENT; FIBRINOGEN; THROMBOMODULIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHILD; COMORBIDITY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DISEASES; DISSEMINATED INTRAVASCULAR CLOTTING; DISSEMINATED INTRAVASCULAR CLOTTING INDUCED BLEEDING; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION; INTRAPLEURAL BLEEDING; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; METABOLISM; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTICOAGULANTS; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRINOGEN; HUMANS; INFECTION; THROMBOMODULIN;

EID: 79961081848     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318204c019     Document Type: Article

References (33)

1. Levi M, Ten Cate H: Disseminated intravascular coagulation. N Engl J Med 341:586-592, 1999.
2. Vincent JL, De Backer D: Does disseminated intravascular coagulation lead to multiple organ failure? Crit Care Clin 21:469-477, 2005.
3. Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, Nelson DR: Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 33: 341-348, 2005.
4. Bakhtiari K, Meijers JCM, de Jonge E, Levi M: Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 32:2416-2421, 2004.
5. Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Nakao S: An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med 29:1164-1168, 2001.
6. Ogura H, Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, et al.: Japanese Association for Acute Medicine Disseminated Intravascular Coagulation Study Group: SIRS-associated coagulopathy and organ dysfunction in critically ill patients with thrombocytopenia. Shock 28:411-417, 2007.
7. Esmon CT, Fukudome K, Mather T, Bode W, Regan LM, Stearns-Kurosawa DJ, Kurosawa S: Inflammation, sepsis, and coagulation. Haematologica 84:254-259, 1999.
8. Ueno H, Hirasawa H, Oda S, Shiga H, Nakanishi K, Matsuda K: Coagulation/fibrinolysis abnormality and vascular endothelial damage in the pathogenesis of thrombocytopenic multiple organ failure. Crit Care Med 30:2242-2248, 2002.
9. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.
10. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, et al.: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869-1878, 2001.
11. Dhainaut JF, Yan SB, Joyce DE, Pettilä V, Basson B, Brandt JT, Sundin DP, Levi M: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2:1924-1933, 2004.
12. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM: Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4:90-97, 2006.
13. Levi M, Toh CH, Thachil J, Watson HG: Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 145:24-33, 2009.
14. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 131:417-430, 2005.
15. Niessen F, Furlan-Freguia C, Fernández JA, Mosnier LO, Castellino FJ, Weiler H, Rosen H, Griffin JH, Ruf W: Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood 113:2859-2866, 2009.
16. Mosnier LO, Zlokovic BV, Griffin JH: The cytoprotective protein C pathway. Blood 109:3161-3172, 2007.
17. Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, et al.: The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kB and mitogen-activated protein kinase pathways. J Exp Med 196:565-577, 2002.
18. Van de Wouwer M, Conway EM: Novel functions of thrombomodulin in inflammation. Crit Care Med 32(Suppl 5):S254-S261, 2004.
19. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, et al.: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 115:1267-1274, 2005.
20. Ito T, Kawahara K, Okamoto K, Yamada S, Yasuda M, Imaizumi H, Nawa Y, Meng X, Shrestha B, Hashiguchi T, et al.: Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 28:1825-1830, 2008.
21. Shi CS, Shi GY, Hsiao SM, Kao YC, Kuo KL, Ma CY, Kuo CH, Chang BI, Chang CF, Lin CH, et al.: Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 112:3661-3670, 2008.
22. Van de Wouwer M, Plaisance S, De Vriese A, Waelkens E, Collen D, Persson J, Daha MR, Conway EM: The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 4:1813-1824, 2006.
23. Gomi K, Zushi M, Honda G, Kawahara S, Matsuzaki O, Kanabayashi T, Yamamoto S, Maruyama I, Suzuki K: Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 75:1396-1399, 1990.
24. Mohri M, Sugimoto E, Sata M, Asano T: The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulationVa comparison with other anticoagulants. Thromb Haemost 82:1687-1693, 1999.
25. Mohri M, Gonda Y, Oka M, Aoki Y, Gomi K, Kiyota T, Sugihara T, Yamamoto S, Ishida T, Maruyama I: The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intra-vascular coagulation in crab-eating monkeys (Macaca fascicularis). Blood Coagul Fibrinolysis 8:274-283, 1997.
26. Nagato M, Okamoto K, Abe Y, Higure A, Yamaguchi K: Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med 37:2181-2186, 2009.
27. Hagiwara S, Iwasaka H, Matsumoto S, Hasegawa A, Yasuda N, Noguchi T: In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models. Shock 33:282-288, 2010.
28. Mohri T, Tanaka H, Tajima G, Kajino K, Sonoi H, Hosotsubo H, Ogura H, Kuwagata Y, Shimazu T, Sugimoto H: Synergistic effects of recombinant human soluble thrombomodulin and fluid-volume resuscitation in a rat lethal crush injury model. Shock 26:581-586, 2006.
29. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, et al.: Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5:31-41, 2007.
30. Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H: Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 49:265-275, 1983.
31. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, et al.: A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 34:625-631, 2006.
32. Wilson RF, Mammen EF, Tyburski JG, Warsow KM, Kubinec SM: Antithrombin levels related to infections and outcome. J Trauma 40:384-387, 1996.
33. Esmon C: Do-all receptor takes on coagulation, inflammation. Nat Med 11: 475-477, 2005.